Bronchiectasis is a chronic and often progressive disease, which frequently is associated with significant symptom burden, requiring intensive treatment. Regardless of the multiple potential underlying aetiologies, the vicious cycle of airway inflammation, structural airway damage, impaired mucus clearance and airway pathogen acquisition is the crucial pathogenic pathway for the progression of disease [1]. Patients with clinically significant bronchiectasis featuring an eosinophilic inflammatory endotype who were treated with add-on mepolizumab or benralizumab showed a significant improvement of FEV1, symptom burden and quality of life http://bit.ly/2AZvBLm

中文翻译：

---

抗 IL5 和抗 IL5Rα 治疗具有临床意义的嗜酸性内型支气管扩张：病例系列

支气管扩张症是一种慢性且通常是进行性的疾病，通常伴有严重的症状负担，需要强化治疗。尽管存在多种潜在的潜在病因，气道炎症、结构性气道损伤、粘液清除受损和气道病原体获取的恶性循环是疾病进展的关键致病途径[1]。具有嗜酸性炎症内型的临床显着支气管扩张患者接受附加美泊利单抗或贝那利珠单抗治疗后，FEV1、症状负担和生活质量均显着改善 http://bit.ly/2AZvBLm